



### **Tanovea: A New Therapy Option for Canine Lymphoma**

Dr. Krystal Harris, DVM (Practice Limited to Oncology)

Tanovea-CA1 (rabacfosadine) was just released for the treatment of naive and relapsed Canine Lymphoma. Tanovea is a unique small molecule designed to selectively accumulate and become activated within lymphocytes. It is the first FDA approved chemotherapy specific to canine lymphoma; the well-known CHOP based therapies are administered off-label in our canine patients.

Tanovea is diluted and administered IV as a 30-minute infusion once every 3 weeks, similar to a doxorubicin protocol but offers a cardio-safe alternative. Overall response rate is reported at 100% in naive dogs and 74% in dogs which have failed prior therapy. So far it has been used as single-agent therapy or alternating with doxorubicin (with concurrent prednisone). Please call our Oncology Service if you have questions about Tanovea. Our VTS in Oncology, Renee, participated in clinical trials of Tanovea adding to our experience and confidence with administration of this new therapy choice.

**Animal Medical Center of Seattle**

**14810 15<sup>th</sup> Ave NE**

**Shoreline, WA 98155**

**P: 206-204-3366 F: 206-204-3858**

**E: [amcsclientservices@specializedcare.pro](mailto:amcsclientservices@specializedcare.pro)**